RCKT up 10%. Is there a catalyst?

Shares of Rocket Pharmaceuticals Inc (RCKT) are trading 8% higher at a price of $15.185 at the time of this writing. While the Health Care sector is having a green day in general, the company is outperforming it's peers. The market is undergoing a small move (0.42, which is unlikely to be the catalyst for the stock's movement.

- Rocket's gene therapy for heart disease is showing promise in children and adults in a phase 1 trial
- The trial is testing the safety and effectiveness of the therapy
- The results are encouraging so far


Rocket Pharmaceuticals Inc has been trading between a 52-week high of $36.87 and a 52-week low of $7.57. The stock has a market cap of $1 Billion.

Rocket Pharmaceuticals, Inc. is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The Company's platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases.

Headlines

Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
Business Wire 09-30-22

Rocket Pharmaceuticals Inc. (RCKT) can beat the pack with these strategies
US Post News 09-27-22

Rocket Pharmaceuticals to Present at Chardan 6th Annual Genetic Medicines Conference
Business Wire 09-27-22

The M&A Class Action Firm Announces an Investigation of Renovacor, Inc. - RCKT
Kwhen Finance 09-22-22

Why SOBR Safe Shares Surged Around 233%; Here Are 68 Biggest Movers From Yesterday
Benzinga 09-21-22